Yahoo
OTC Markets OTCPK - Delayed Quote USD

Ono Pharmaceutical Co., Ltd. (OPHLY)

5.06 -0.04 (-0.78%)
At close: 3:24:24 PM EST
View in AlphaSpace Currency in JPY All numbers in thousands
Financial statements have been upgraded
A new layout with more detail in every statement.
TTM
3/31/2026
3/31/2025
3/31/2024
3/31/2023
Total Revenue
491,153,000 515,785,000 486,871,000 502,672,000 447,187,000
Cost of Revenue
-127,170,000 -141,716,000 -147,950,000 -127,126,000 -110,062,000
Gross Profit
363,983,000 374,069,000 338,921,000 375,547,000 337,124,000
Selling, General and Administrative Expenses
-110,444,000 -123,691,000 -125,671,000 -100,270,000 -89,486,000
Research and Development Expenses
-145,115,000 -147,043,000 -149,866,000 -112,174,000 -95,344,000
Other Income/Expense, Operating
-10,350,000 -11,099,000 -3,636,000 -3,167,000 -10,331,000
Operating Income/Expenses
-265,909,000 -281,833,000 -279,173,000 -215,611,000 -195,161,000
Total Operating Profit/Loss
98,074,000 92,236,000 59,748,000 159,936,000 141,963,000
Total Net Finance Income/Expense
822,000 417,000 -544,000 3,798,000 1,565,000
Net Investment Income
0 0 125,000 1,000 4,000
Non-Operating Income/Expenses, Total
822,000 417,000 -419,000 3,799,000 1,569,000
Pretax Income
98,897,000 92,654,000 59,328,000 163,734,000 143,532,000
Provision for Income Tax
-23,936,000 -22,743,000 -9,163,000 -35,694,000 -30,619,000
Net Income from Continuing Operations
74,961,000 69,911,000 50,165,000 128,040,000 112,913,000
Net Income after Extraordinary Items and Discontinued Operations
74,962,000 69,911,000 50,166,000 128,040,000 112,913,000
Non-Controlling/Minority Interests
-353,000 -144,000 -119,000 -62,000 -190,000
Net Income after Non-Controlling/Minority Interests
74,608,000 69,767,000 50,047,000 127,977,000 112,723,000
Net Income Available to Common Stockholders
74,608,000 69,767,000 50,047,000 127,977,000 112,723,000
Diluted Net Income Available to Common Stockholders
74,608,000 69,767,000 50,047,000 127,977,000 112,723,000
Basic EPS
52.91 49.49 35.51 88.86 76.94
Diluted EPS
52.87 49.47 35.47 88.85 76.92
Basic Weighted Average Shares Outstanding
1,409,452.45 1,409,219.92 1,409,696.97 1,440,191.28 1,465,032.79
Diluted Weighted Average Shares Outstanding
1,410,095.56 1,409,444.94 1,410,057.01 1,440,407.39 1,465,413.67
Reported Normalized Basic EPS
73.42 73.42 -- -- --
Income Statement, Supplemental
EBIT
98,075,000 92,237,000 59,872,000 159,936,000 141,967,000
EBITDA
135,330,000 129,989,000 86,766,000 178,076,000 159,418,000
Normalized EBITDA
135,330,000 132,189,000 94,747,000 192,961,000 160,916,000
Normalized Income
74,961,000 103,499,000 90,361,000 142,545,000 114,091,926
Total Unusual Items
0 2,200,000 7,981,000 14,885,000 1,498,000
3/31/2023 - 10/2/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: